|
1
|
Masters CL, Bateman R, Blennow K, Rowe CC,
Sperling RA and Cummings JL: Alzheimer's disease. Nat Rev Dis
Primers. 1(15056)2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hardy JA and Higgins GA: Alzheimer's
disease: The amyloid cascade hypothesis. Science. 256:184–185.
1992.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wang X, Perumalsamy H, Kwon HW, Na YE and
Ahn YJ: Effects and possible mechanisms of action of acacetin on
the behavior and eye morphology of Drosophila models of Alzheimer's
disease. Sci Rep. 5(16127)2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tao CC, Cheng KM, Ma YL, Hsu WL, Chen YC,
Fuh JL, Lee WJ, Chao CC and Lee EHY: Galectin-3 promotes Aβ
oligomerization and Aβ toxicity in a mouse model of Alzheimer's
disease. Cell Death Differ. 27:192–209. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
De S, Whiten DR, Ruggeri FS, Hughes C,
Rodrigues M, Sideris DI, Taylor CG, Aprile FA, Muyldermans S,
Knowles TPJ, et al: Soluble aggregates present in cerebrospinal
fluid change in size and mechanism of toxicity during Alzheimer's
disease progression. Acta Neuropathol Commun. 7(120)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gu X, Wu H, Xie Y, Xu L, Liu X and Wang W:
Caspase-1/IL-1β represses membrane transport of GluA1 by inhibiting
the interaction between Stargazin and GluA1 in Alzheimer's disease.
Mol Med. 27(8)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang S, Ma F, Huang L, Zhang Y and Peng Y,
Xing C, Feng Y, Wang X and Peng Y: Dl-3-n-butylphthalide (NBP): A
promising therapeutic agent for ischemic stroke. CNS Neurol Disord
Drug Targets. 17:338–347. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cheng X, Wang H, Liu C, Zhong S, Niu X,
Zhang X, Qi R, Zhao S, Zhang X, Qu H and Zhao C:
Dl-3-n-butylphthalide promotes remyelination process in cerebral
white matter in rats subjected to ischemic stroke. Brain Res.
1717:167–175. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chong ZZ and Feng YP:
DI-3-n-butylphthalide improves regional cerebral blood flow after
experimental subarachnoid hemorrhage in rats. Zhongguo Yao Li Xue
Bao. 20:509–512. 1999.PubMed/NCBI
|
|
10
|
Wu F, Xu K, Xu K, Teng C, Zhang M, Xia L,
Zhang K, Liu L, Chen Z, Xiao J, et al: Dl-3n-butylphthalide
improves traumatic brain injury recovery via inhibiting
autophagy-induced blood-brain barrier disruption and cell
apoptosis. J Cell Mol Med. 24:1220–1232. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing
Z, Xiang Y, Li W, Tsang CK, Ruan Y and Huang L:
Dl-3-n-butylphthalide treatment enhances hemodynamics and
ameliorates memory deficits in rats with chronic cerebral
hypoperfusion. Front Aging Neurosci. 9(238)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lv C, Ma Q, Han B, Li J, Geng Y, Zhang X
and Wang M: Long-term DL-3-n-butylphthalide treatment alleviates
cognitive impairment correlate with improving synaptic plasticity
in SAMP8 mice. Front Aging Neurosci. 10(200)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen XQ, Qiu K, Liu H, He Q, Bai JH and Lu
W: Application and prospects of butylphthalide for the treatment of
neurologic diseases. Chin Med J (Engl). 132:1467–1477.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu CY, Zhao ZH, Chen ZT, Che CH, Zou ZY,
Wu XM, Chen SG, Li YX, Lin HB, Wei XF, et al: DL-3-n-butylphthalide
protects endothelial cells against advanced glycation end
product-induced injury by attenuating oxidative stress and
inflammation responses. Exp Ther Med. 14:2241–2248. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang G, Zhang J, Hu X, Zhang L, Mao L,
Jiang X, Liou AK, Leak RK, Gao Y and Chen J: Microglia/macrophage
polarization dynamics in white matter after traumatic brain injury.
J Cereb Blood Flow Metab. 33:1864–1874. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Liao D, Xiang D, Dang R, Xu P, Wang J, Han
W, Fu Y, Yao D, Cao L and Jiang P: Neuroprotective effects of
dl-3-n-butylphthalide against doxorubicin-induced
neuroinflammation, oxidative stress, endoplasmic reticulum stress,
and behavioral changes. Oxid Med Cell Longev.
2018(9125601)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
He RJ, Yu ZH, Zhang RY and Zhang ZY:
Protein tyrosine phosphatases as potential therapeutic targets.
Acta Pharmacol Sin. 35:1227–1246. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jang SS, Royston SE, Lee G, Wang S and
Chung HJ: Seizure-induced regulations of amyloid-β, STEP61, and
STEP61 substrates involved in hippocampal synaptic plasticity.
Neural Plast. 2016(2123748)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang L, Xie JW, Yang J and Cao YP:
Tyrosine phosphatase STEP61 negatively regulates amyloid β-mediated
ERK/CREB signaling pathways via α7 nicotinic acetylcholine
receptors. J Neurosci Res. 91:1581–1590. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press, Washington, DC, 2011.
|
|
21
|
Zhuang XX, Zang X, Zheng GY, Hua N, Sun Y,
Hu YH and He L: Polyprenols mitigate cognitive dysfunction and
neuropathology in the APP/PS1 mouse. Phytother Res. 32:1098–1107.
2018.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Poddar R, Rajagopal S, Shuttleworth CW and
Paul S: Zn2+-dependent activation of the Trk signaling pathway
induces phosphorylation of the brain-enriched tyrosine phosphatase
STEP: Molecular basis for ZN2+-induced ERK MAPK activation. J Biol
Chem. 291:813–825. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Goebel-Goody SM, Baum M, Paspalas CD,
Fernandez SM, Carty NC, Kurup P and Lombroso PJ: Therapeutic
implications for striatal-enriched protein tyrosine phosphatase
(STEP) in neuropsychiatric disorders. Pharmacol Rev. 64:65–87.
2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Paul S, Nairn AC, Wang P and Lombroso PJ:
NMDA-mediated activation of the tyrosine phosphatase STEP regulates
the duration of ERK signaling. Nat Neurosci. 6:34–42.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Lugo JN, Brewster AL, Spencer CM and
Anderson AE: Kv4.2 knockout mice have hippocampal-dependent
learning and memory deficits. Learn Mem. 19:182–189.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Owona BA, Zug C, Schluesener HJ and Zhang
ZY: Amelioration of behavioral impairments and neuropathology by
antiepileptic drug topiramate in a transgenic Alzheimer's disease
model mice, APP/PS1. Int J Mol Sci. 20(3003)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang P, Yang YH, Chang YH, Chang SL, Chou
MC, Lai CL, Liu CK and Chen HY: Association of early-onset
Alzheimer's disease with germline-generated high affinity
self-antigen load. Transl Psychiatry. 10(146)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bush AI and Tanzi RE: Therapeutics for
Alzheimer's disease based on the metal hypothesis.
Neurotherapeutics. 5:421–432. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kamceva M, Benedict J, Nairn AC and
Lombroso PJ: Role of striatal-enriched tyrosine phosphatase in
neuronal function. Neural Plast. 2016(8136925)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Huang L, Lan J, Tang J, Kang Y, Feng X, Wu
L and Peng Y: L-3-n-butylphthalide improves synaptic and dendritic
spine plasticity and ameliorates neurite pathology in Alzheimer's
disease mouse model and cultured hippocampal neurons. Mol
Neurobiol. 58:1260–1274. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang Y, Huang LJ, Shi S, Xu SF, Wang XL
and Peng Y: L-3-n-butylphthalide rescues hippocampal synaptic
failure and attenuates neuropathology in aged APP/PS1 mouse model
of Alzheimer's disease. CNS Neurosci Ther. 22:979–987.
2016.PubMed/NCBI View Article : Google Scholar
|
